Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Barcelona.

The European trials studied the effectiveness, safety and tolerability of the treatment in patients with spasticity symptoms in Multiple Sclerosis

Sativex is the first prescription medicine based on cannabinoids, active ingredients tetrahydrocannabinol (THC) and cannabidiol (CBD) extracted from the Cannabis sativa plant, an add-on therapy indicated to treat symptoms of moderate or severe spasticity in people with multiple sclerosis who are not responding to other antispastic treatments.

The study tested a population of 1,534 Italian patients with MS. A high initial response rate was observed, with more than 60% of patients continuing treatment after the first-month trial period once proving enough effect (>20% spasticity improvement from baseline) and acceptable tolerability.

About 25% of these patients already showed...